Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of Licartin to reduce recurrence after hepatocellular carcinoma resection or ablation
ChiCTR-TRC-14004643Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of licofelone in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Blood routine examination, Renal function and 5 more. Started Sep 2013; status: recruiting.
02
Drugs
licofelone
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-14004643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004643.